Moreover, inhibition of SGK1 improves the aggregation of α-syn in glial cells in an in vitro model of α-syn pathology (Kwon et al., 2021), further implying that SGK1 inhibition is beneficial for the treatment of PD. This evidence concerns the gene SGK1 and Parkinson disease.